CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Roma, Italy and 213 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Roma, Italy and 125 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Roma, RM, Italy and 92 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Roma, Italy and 176 other locations
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...
Phase 2
Roma, Italy and 20 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Rome, Italy and 117 other locations
This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score \>1 positive ovarian, Fa...
Phase 2
Rome, Italy
of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...
Phase 2
Roma, Italy and 77 other locations
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, ...
Phase 3
Rome, Italy and 7 other locations
as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high fola...
Phase 3
Rome, Italy and 151 other locations
Clinical trials
Research sites
Resources
Legal